Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
Ianniello A, Sansovini M, Severi S, Nicolini S, Grana CM, Massri K, Bongiovanni A, Antonuzzo L, Di Iorio V, Sarnelli A, Caroli P, Monti M, Scarpi E, Paganelli G. Ianniello A, et al. Among authors: sarnelli a. Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1040-6. doi: 10.1007/s00259-015-3262-8. Epub 2015 Nov 27. Eur J Nucl Med Mol Imaging. 2016. PMID: 26611427 Clinical Trial.
3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART) combined with external beam radiation therapy.
Ferrari ME, Cremonesi M, Di Dia A, Botta F, De Cicco C, Sarnelli A, Pedicini P, Calabrese M, Orecchia R, Pedroli G, Paganelli G. Ferrari ME, et al. Among authors: sarnelli a. Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1702-11. doi: 10.1007/s00259-012-2197-6. Epub 2012 Aug 14. Eur J Nucl Med Mol Imaging. 2012. PMID: 22890802
Kidney dosimetry in ¹⁷⁷Lu and ⁹⁰Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors.
Guerriero F, Ferrari ME, Botta F, Fioroni F, Grassi E, Versari A, Sarnelli A, Pacilio M, Amato E, Strigari L, Bodei L, Paganelli G, Iori M, Pedroli G, Cremonesi M. Guerriero F, et al. Among authors: sarnelli a. Biomed Res Int. 2013;2013:935351. doi: 10.1155/2013/935351. Epub 2013 Jun 20. Biomed Res Int. 2013. PMID: 23865075 Free PMC article. Clinical Trial.
Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations.
Sarnelli A, Guerriero F, Botta F, Ferrari M, Strigari L, Bodei L, D'Errico V, Grassi E, Fioroni F, Paganelli G, Orecchia R, Cremonesi M. Sarnelli A, et al. Q J Nucl Med Mol Imaging. 2017 Jun;61(2):216-231. doi: 10.23736/S1824-4785.16.02744-8. Epub 2015 Nov 17. Q J Nucl Med Mol Imaging. 2017. PMID: 26576734
Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results.
Matteucci F, Mezzenga E, Caroli P, Di Iorio V, Sarnelli A, Celli M, Fantini L, Moretti A, Galassi R, De Giorgi U, Paganelli G. Matteucci F, et al. Among authors: sarnelli a. Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2189-2194. doi: 10.1007/s00259-017-3791-4. Epub 2017 Aug 11. Eur J Nucl Med Mol Imaging. 2017. PMID: 28801787
Quantitative accuracy of 177Lu SPECT imaging for molecular radiotherapy.
Mezzenga E, D'Errico V, D'Arienzo M, Strigari L, Panagiota K, Matteucci F, Severi S, Paganelli G, Fenwick A, Bianchini D, Marcocci F, Sarnelli A. Mezzenga E, et al. Among authors: sarnelli a. PLoS One. 2017 Aug 14;12(8):e0182888. doi: 10.1371/journal.pone.0182888. eCollection 2017. PLoS One. 2017. PMID: 28806773 Free PMC article.
High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment.
Parisi E, Romeo A, Sarnelli A, Ghigi G, Bellia SR, Neri E, Micheletti S, Dipalma B, Arpa D, Furini G, Burgio MA, Genestreti G, Gurioli C, Sanna S, Bovolato P, Rea F, Storme G, Scarpi E, Arienti C, Tesei A, Polico R. Parisi E, et al. Among authors: sarnelli a. Cancer Radiother. 2017 Dec;21(8):766-773. doi: 10.1016/j.canrad.2017.05.007. Epub 2017 Nov 11. Cancer Radiother. 2017. PMID: 29132803
Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning.
Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, Pacilio M, Strigari L, Summers PE, Orecchia R, Grana CM, Botta F. Cremonesi M, et al. Among authors: sarnelli a. Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2426-2441. doi: 10.1007/s00259-018-4044-x. Epub 2018 May 21. Eur J Nucl Med Mol Imaging. 2018. PMID: 29785514 Free PMC article. Review.
73 results